Tenders in Germany
8,131 open tenders available
Open House Biologics discount agreements 2026-24 - Aflibercept (ATC: S01LA05; potency: 40 mg/ml)
TECHNICIANS' HEALTH INSURANCE
<br/>The TK pursues the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with Section 130a Paragraph 8 SGB V for ...
Conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for the active ingredients mentioned with the possibility of conclusion within the framework of the so-called open house procedure.
KKH COMMERCIAL HEALTH INSURANCE COMPANY
<br/>The Kaufmännische Krankenkasse - KKH (hereinafter KKH) pursues the goal of concluding discount agreements with all suitable pharmaceutical companies in acc...
Open House Biologics Discount Agreements 2025-25 - Aflibercept (ATC: S01LA05; Potency: 40 mg/ml)
TECHNICIANS' HEALTH INSURANCE
<br/>The TK pursues the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with Section 130a Paragraph 8 SGB V for ...
Open House Biologics Discount Agreements 2026-23 - Darbepoetin alfa
TECHNICIANS' HEALTH INSURANCE
<br/>The TK pursues the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with Section 130a Paragraph 8 SGB V for ...
Conclusion of a non-exclusive framework agreement for planning traffic facilities 2025 ff. in the open house process of the federal Autobahn GmbH (OH-ZEN-2025_01)
THE FEDERAL AUTOBAHN GMBH
<br/>The subject of lot/service area 01 are planning services for simple route maintenance measures (at least pavement renewal) with simple boundary conditions,...
Open framework agreement on drug discounts in accordance with Section 130a Paragraph 8 SGB V with the possibility of joining at any time, so-called approval model 2026-07
GERMAN PENSION INSURANCE KNAPPSCHAFT-BAHN-SEE
<br/>This announcement serves to conclude agreements with pharmaceutical companies within the meaning of Section 130a Paragraph 8 Sentence 1 SGB V. The invitati...
Conclusion not excluding drug discount agreement. according to Section 130a Paragraph 8 SGB V through an open house model for the active ingredient oxycodone/naloxone (ATC code according to WHO: N02AA55)
AOK PLUS - THE HEALTH INSURANCE FUND FOR SAXONY AND THURINGIA
<br/>The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for medicines with...
Medicines with the active ingredient filgrastim (ATC: L03AA02)
AOK SAXONY - ANHALT
<br/>The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for finished medic...
Medicines with the active ingredient teriparatide (ATC: H05AA02)
AOK SAXONY - ANHALT
<br/>The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for finished medic...
Medicines with the active ingredient denosumab (ATC: M05BX04)
AOK SAXONY - ANHALT
<br/>The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for finished medic...
Medicines with the active ingredient ustekinumab (ATC: L04AC05)
AOK SAXONY - ANHALT
<br/>The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a Paragraph 8 SGB V for finished medic...
